



UNIVERSITY OF LEEDS

This is a repository copy of *Commentary on Viewpoint: The interaction between SARS-CoV-2 and ACE2 may have consequences for skeletal muscle viral susceptibility and myopathies.*

White Rose Research Online URL for this paper:  
<https://eprints.whiterose.ac.uk/166623/>

Version: Accepted Version

---

**Article:**

Tan, AL [orcid.org/0000-0002-9158-7243](https://orcid.org/0000-0002-9158-7243), Farrow, M and Biglands, J (2020) Commentary on Viewpoint: The interaction between SARS-CoV-2 and ACE2 may have consequences for skeletal muscle viral susceptibility and myopathies. *Journal of Applied Physiology*, 129 (4). p. 868. ISSN 8750-7587

<https://doi.org/10.1152/jappphysiol.00775.2020>

---

© 2020 the American Physiological Society This is an author produced version of an article published in *Journal of Applied Physiology*. Uploaded in accordance with the publisher's self-archiving policy.

**Reuse**

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

**Commentaries on Viewpoint: The interaction between SARS-CoV-2 and ACE2 may have consequences for skeletal muscle viral susceptibility and myopathies**

Ai Lyn Tan<sup>1,2</sup>, Matthew Farrow<sup>1,2,3</sup>, John Biglands<sup>1,4</sup>

<sup>1</sup>NIHR Leeds Biomedical Research Centre, Chapel Allerton Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, UK

<sup>2</sup>Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.

<sup>3</sup>School of Pharmacy and Medical Sciences, University of Bradford, UK.

<sup>4</sup>Medical Physics and Engineering, Leeds Teaching Hospitals NHS Trust, Leeds, UK.

A. L. Tan, ORCID: 0000-0002-9158-7243

J. Biglands, ORCID: 0000-0002-1161-5022

Email: [a.l.tan@leeds.ac.uk](mailto:a.l.tan@leeds.ac.uk)

Address for correspondence: Leeds Institute of Rheumatic and Musculoskeletal Medicine  
Chapel Allerton Hospital  
Chapeltown Road  
Leeds LS4 7SA  
UK

With emerging knowledge regarding the pathogenesis involving SARS-CoV-2, it is becoming apparent that no tissue is spared in the body. Ferrandi et al (5) suggested a cause for myopathy in COVID-19 via the ACE2 expression that leads to myocytes becoming susceptible to SARS-CoV-2. We would like to add that, the muscle involvement in COVID-19 is likely to be early in the infection. We have recently explored the muscles in rheumatoid arthritis (RA) (4) using quantitative MRI measures, which reflect physiological changes regarded as an indirect measure of muscle inflammation (3). These abnormal muscle changes which are present in established RA patients, are also noticeable in newly diagnosed untreated RA patients. This suggests that muscle is likely to be sensitive to the inflammatory process and is involved early. COVID-19 also involves multiple pro-inflammatory cytokines; the muscles may already be affected in susceptible patients at the time of diagnosis, which may then lead to various muscle related pathologies including affecting the respiratory muscles as eluded to by Ferrandi et al. Further, Ferrandi et al highlighted that the aging population are at increased risk of COVID-19; we showed that there are age-related muscle changes on MRI that correlates with frailty and muscle function (2). Our RA patients, when treated to arthritis remission, continued to have persistent abnormal MRI changes and weaker muscles. This is analogous to patients who 'recovered' from COVID-19, but continue to manifest various muscular symptoms (1). Therefore therapeutic strategies targeting the muscle may be important throughout the course of COVID-19.

## References

1. **Disser NP, De Micheli AJ, Schonk MM, Konnaris MA, Piacentini AN, Edon DL, Toresdahl BG, Rodeo SA, Casey EK, and Mendias CL.** Musculoskeletal Consequences of COVID-19. *The Journal of bone and joint surgery American volume* 102: 1197-1204, 2020.
2. **Farrow M, Biglands J, Tanner SF, Clegg A, Brown L, Hensor EMA, O'Connor P, Emery P, and Tan AL.** The effect of ageing on skeletal muscle as assessed by quantitative MR imaging: an association with frailty and muscle strength. *Aging clinical and experimental research* 2020.
3. **Farrow M BJ, Alfuraih AM, Wakefield RJ, Tan AL.** Novel muscle imaging in inflammatory rheumatic diseases – a focus on ultrasound shear wave elastography and quantitative MRI *Front Med* In press: 2020.
4. **Farrow M BJ, Tanner S, Hensor EMA, Buch M, Emery P, Tan AL.** Muscle deterioration due to rheumatoid arthritis: assessment by quantitative MRI and strength testing. *Rheumatology (Oxford)* In press: 2020.
5. **Ferrandi PJ, Alway SE, and Mohamed JS.** The interaction between SARS-CoV-2 and ACE2 may have consequences for skeletal muscle viral susceptibility and myopathies. *Journal of applied physiology (Bethesda, Md : 1985)* 2020.